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Abstract
Introduction Colorectal cancer is the fourth leading cause of cancer mortality in developed countries. There is evidence
supporting a disproportionate loss of skeletal muscle as an independent prognostic factor. The importance of the systemic
inflammatory response as a unifying mechanism for specific loss of skeletal muscle mass in patients with cancer is increasingly
recognized. The aim of the present study was to delineate the relationship between the systemic inflammatory response,
skeletal muscle index (SMI), skeletal muscle density (SMD), and overall survival in patients with colorectal cancer.
Materials and methods The study included 650 patients with primary operable colorectal cancer. Computed tomography
scans were used to define the presence of visceral obesity, sarcopenia (low SMI), and myosteatosis (low SMD). Tumour and
patient characteristics were recorded. Survival analysis was carried out using univariate and multivariate Cox regression.
Results A total of 650 patients (354 men and 296 women) were included. The majority of patients were over 65 years of
age (64%) and overweight or obese (68%). On univariate survival analysis, age, ASA, TNM stage, modified Glasgow Prognostic
Score (mGPS), body mass index, subcutaneous fat index, visceral obesity, SMI, and SMD were significantly associated
with overall survival (all P < 0.05). A low SMI and SMD were significantly associated with an elevated mGPS (<0.05).
On multivariate analysis, SMI (Martin) [hazard ratio (HR) 1.50, 95% confidence interval (CI) 1.04–2.18, P = 0.031], SMD (Xiao)
(HR 1.42, 95% CI 0.98–2.05, P = 0.061), and mGPS (HR 1.44, 95% CI 1.15–1.79, P = 0.001) were independently associated
with overall survival. SMD but not SMI was significantly associated with ASA (P < 0.001).
Conclusions This study delineates the relationship between the loss of quantity and quality of skeletal muscle mass,
the systemic inflammatory response, and survival in patients with operable colorectal cancer.
Keywords Colorectal cancer; TNM stage; Systemic inflammation; Glasgow prognostic score; Body composition; Computed
tomography
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Introduction
Colorectal cancer (CRC) is the fourth leading cause of cancer
mortality in developed countries.1 Despite death rates from
CRC falling by ~14% over the last decade, ~40% of those diag-
nosed will die from their cancer. Similar to most common
solid tumours, disease progression is associated with a
progressive nutritional and functional decline resulting in
poor response to treatment and poor survival.2,3
In the past, weight loss and body mass index (BMI) have
been used as an indicator of such nutritional decline and poor
prognosis.2,3 However, because of the increased number of
patients presenting in an overweight or obese state in the
developed world, the use of simple weight loss and BMI as
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a prognostic indicator has been questioned.4–7 The ability to
use routine computed tomography (CT) scans to measure
body composition, in particular skeletal muscle, has resulted
in a marked increase in interest in using skeletal muscle index
(SMI) and skeletal muscle density (SMD) to predict outcomes
in patients with cancer, particularly in CRC.8
There is evidence supporting a disproportionate loss of
skeletal muscle tissue to be an independent prognostic factor
for both cancer specific and overall survival in patients with
CRC.9 Specifically, muscle loss has been associated with poor
treatment tolerance and efficacy,10 worse quality of life, and
increased morbidity.11 For example, in a large study, Caan
et al. reported that in patients with CRC, there was a signifi-
cant association between lower SMI and worse overall
survival.12 Also, Malietzis et al. reported that in patients
with CRC, there was a significant association between lower
SMD and worse overall survival.13
The importance of the systemic inflammatory response as
a unifying mechanism for weight loss and loss of lean tissue
in patients with cancer is increasingly recognized.3,14,15
Therefore, it is of interest that SMI and SMD have been
repeatedly reported to be inversely associated with measures
of the systemic inflammatory response, such as the neutro-
phil lymphocyte ratio (NLR) and modified Glasgow prognostic
score (mGPS),16–22 that are recognized to have prognostic
value in their own right.23,24 However, this relationship is
not clear. It is possible that some patients with sarcopenia
may have systemic inflammation and some patients with
myosteatosis might similarly have systemic inflammation,
but the coexistence of those three features is poorly under-
stood. If the above association was due to the erosion of
the SMI and SMD by an ongoing systemic inflammatory re-
sponse, it might be anticipated that the prognostic value of
SMI and SMD was largely dependent on the presence of a
systemic inflammatory response. It might also be anticipated
that low SMI and SMD would influence the relationship
between the systemic inflammatory response and survival.
To our knowledge, no study has comprehensively exam-
ined the relationship between CT-derived body composition,
systemic inflammatory response, as measured by the mGPS,
and survival in patients with primary operable CRC. There-
fore, the aim of the present study was to examine the above
relationships in a prospectively maintained database of
patients with CRC undergoing potentially curative resection.
Materials and methods
Patients
Consecutive patients who underwent elective, potentially
curative resection for CRC between March 2008 and June
2017 at a single centre were identified from a prospectively
maintained database. Those patients with a pre-operative
CT scan and a recorded height and weight were included.
Patients were classified according to BMI as underweight
(BMI < 18.5), normal weight (BMI 18.5–24.9), overweight
(BMI 25.0–29.9), and obese (BMI ≥ 30) and were recorded.
All tumours were staged according to TNM fifth edition.
Pre-operative haematological and biochemical markers were
recorded.
The cause and date of death were confirmed with the Reg-
istrar General (Scotland) until 1 June 2017 that served as the
censor date. Informed consent was obtained from patients
prior to surgery. Those with metastatic CRC and those who
underwent emergency surgery or palliative surgery were
excluded from the study. Ethical approval was granted by
the West of Scotland Research Ethics Committee, Glasgow.
Methods
Computed tomography images were obtained at the level of
the third lumbar vertebra as previously described.16 Patients
whose scans were taken 3 months or more prior to their
surgery were excluded from the study. Scans with significant
movement artefact or missing region of interest were not con-
sidered for inclusion. Each image was analysed using a free-
ware programme (NIH ImageJ version 1.47, http://rsbweb.
nih.gov/ij/) shown to provide reliable measurements.22
Region of interest measurements were made of visceral fat
area (VFA), subcutaneous fat area, and skeletal muscle area
(cm2) using standard Hounsfield unit (HU) ranges (adipose
tissue 190 to 30 and skeletal muscle 29 to +150).
These were then normalized for height2 to create indices:
subcutaneous fat index (SFI, cm2/m2) and SMI (cm2/m2). Skel-
etal muscle radiodensity (SMD, HU) was measured from the
same region of interest used to calculate SMI, as its mean HU.
Visceral obesity was defined as VFA > 160 cm2 for male
patients and >80 cm2 for female patients.25 Sarcopenia
was defined as described by Martin et al. as an
SMI < 43 cm2/m2 if BMI < 25 kg/m2 and SMI < 53 cm2/m2
if BMI ≥ 25 kg/m2 in male patients and an SMI < 41 cm2/m2
in female patients.6 Sarcopenia was also described by Caan
et al. as an SMI < 52.3 cm2/m2 if BMI < 30 kg/m2 and
SMI< 54.3 cm2/m2 if BMI ≥ 30 kg/m2 in male patients and an
SMI< 38.6 cm2/m2 if BMI< 30 kg/m2 and SMI< 46.6 cm2/m2
if BMI ≥ 30 kg/m2 in female patients.12 Myosteatosis was
defined by Martin et al. as an SMD < 41 HU in patients with
BMI < 25 kg/m2 and <33 HU in patients with
BMI > 25 kg/m2.6 Myosteatosis was also defined by Xiao
et al. as <35.5 HU in men and <32.5 HU in women.26
Subcutaneous fat index was defined as ≥50.0 cm2/m2 in
men and ≥42.0 cm2/m2 in women27 (Table 1).
Measurements were performed by two individuals (A. S. A.
and L. B. D.), and inter-rater reliability was assessed in a
sample of 30 patient images using inter-class correlation
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coefficients (ICCCs) (total fat area ICCC = 1.000; subcutaneous
fat area ICCC = 1.000; VFA ICCC = 1.000; skeletal muscle
area ICCC = 0.998; and SMD ICCC = 0.972). Investigators
were blind to patient’s demographic and clinicopathological
status.
An autoanalyser was used to measure serum C-reactive
protein (mg/L) and albumin (g/L) concentrations (Architect;
Abbot Diagnostics, Maidenhead, UK). The mGPS, NLR,
and neutrophil-platelet score were derived as previously
described.28
Statistical analysis
Body composition measurements were presented as median
and range and compared using Mann–Whitney or Kruskal–
Wallis tests. Categorical variables were analysed using χ2 test
for linear-by-linear association or χ2 test for two-by-two
tables.
Mortality within 30 days of the index procedure or during
the index admission was excluded from subsequent survival
analysis. The time between the date of surgery and the date
of death of any cause was used to define overall survival.
Survival data were analysed using univariate and multivariate
Cox regression. Those variables associated with a degree of
P < 0.1 were entered into a backward conditional multivari-
ate model.
Missing data were excluded from analysis on a variable-by-
variable basis. Two-tailed P-values < 0.05 were considered
statistically significant. Statistical analysis was performed
using SPSS software (version 21.0; SPSS Inc., Chicago, IL, USA).
Results
In the present study, although ImageJ software was used to
calculate body composition parameters, the SMI and SMD
threshold values used were from the Martin and Caan groups
who both used Slice-O-Matic software.6 However, Richards
et al. compared Slice-O-Matic and ImageJ calculated results
in 174 patients with primary operable CRC with an ICCC of
0.953 (P < 0.01).16 Therefore, the use of ImageJ software
was unlikely to introduce a large error unto the present
results. Indeed, the use of such open source software is likely
to facilitate comparison of studies across different cancer
types and research institutions.
In total, 832 patients were identified as having undergone
potentially curative surgery for CRC. Of these, 182
were excluded because of missing eligible CT scans,
Table 1 Computed tomography-derived body composition measures and thresholds used
Body Composition Measurement Frequency n (%)
High SFI27:
Males>50.0 cm2m2 and Females>42.0 cm2m2 No: 116 (17.8%)
Yes: 534 (82.2%)
Visceral obesity5,6:
VFA: Males >160 cm2 and Females >80 cm2 No: 177 (27.2%)
Yes: 473 (72.8%)
Sarcopenia
SMI (Martin)6:
Males: BMI < 25 kg/m2 and SMI < 43 cm2 m2 or BMI ≥ 25 kg/m2 and SMI < 53 cm2 m2
Females: BMI < 25 kg/m2 and SMI < 41 cm2 m2 or BMI ≥ 25 kg/m2 and SMI < 41 cm2 m2
No: 367 (56.5%)
Yes: 283 (43.5%)
SMI (Dolan BMI ≥ 25):
Males: BMI < 25 kg/m2 and SMI < 45 cm2 m2 or BMI ≥ 25 kg/m2 and SMI < 53 cm2 m2
Females: BMI < 25 kg/m2 and SMI < 39 cm2 m2 or BMI ≥ 25 kg/m2 and SMI < 41 cm2 m2
No: 371 (57.1%)
Yes: 279 (42.9%)
SMI (Caan)12:
Males: BMI < 30 kg/m2 and SMI < 52.3 cm2 m2 or BMI ≥ 30 kg/m2 and SMI < 54.3 cm2 m2
Females: BMI < 30 kg/m2 and SMI < 38.6 cm2 m2 or BMI ≥ 30 kg/m2 and SMI < 46.6 cm2 m2
No: 313 (48.2%)
Yes: 337 (51.8%)
SMI (Dolan BMI ≥ 30)
Males: BMI < 30 kg/m2 and SMI < 45.6 cm2 m2 or BMI ≥ 30 kg/m2 and SMI < 56.8 cm2 m2
Females: BMI < 30 kg/m2 and SMI < 39.1 cm2 m2 or BMI ≥ 30 kg/m2 and SMI < 44.6 cm2 m2
No: 386 (59.4%)
Yes: 264 (40.6%)
Myosteatosis
SMD (Martin)6:
BMI < 25 kg/m2 and SMD < 41 HU or BMI ≥ 25 kg/m2 and SMD < 33HU No: 258 (39.7%)
Yes: 392 (60.3%)
SMD (Dolan BMI ≥ 25)
BMI < 25 kg/m2 and SMD < 34 HU or BMI ≥ 25 kg/m2 and SMD < 32HU No: 343 (52.8%)
Yes: 307 (47.2%)
SMD (Xiao)26:
Males<35.5HU and Females<32.5HU No: 309 (47.5%)
Yes: 341 (52.5%)
SMD (Dolan Male/Female)
Males<34.1 HU and Females<HU 34.4 HU No: 304 (46.8%)
Yes: 346 (53.2%)
BMI, body mass index; SFI, subcutaneous fat index; SMD, skeletal muscle density; SMI, skeletal muscle index; VFA, visceral fat area.
CT body composition, inflammation and survival in cancer 113
Journal of Cachexia, Sarcopenia and Muscle 2019; 10: 111–122
DOI: 10.1002/jcsm.12357
clinicopathological data, or blood test results. A further five
patients were excluded as they died in the immediate post-
operative period. A total of 650 patients (354 men and 296
women) were included in the final analyses.
There have been a number of definitions of SMI using CT
scans. Nevertheless, it is clear that muscle mass varies in
male and female patients and with BMI. Skeletal muscle
index has been defined differently in male and female
Table 2 The relationship between clinicopathological characteristics, computed tomography-derived body composition, and survival in patients under-
going elective surgery for colorectal cancer (n = 650): univariate survival analysis
Characteristic n = 650 (%) Overall survival HR (95% CI) P-value
Clinicopathological
Age ≤65 234 (36.0) 1.64 (1.29–2.08) <0.001
65–74 251 (38.6)
>74 165 (25.4)
Sex Female 296 (45.5) 1.19 (0.83–1.70) 0.351
Male 354 (54.5)
ASA score 1 141 (21.7) 1.56 (1.23–1.97) <0.001
2 297 (45.7)
3 193 (29.7)
4 19 (2.9)
Laparoscopic surgery No 407 (62.6) 0.68 (0.45–1.03) 0.072
Yes 243 (37.4)
TNM 0 14 (2.2) 1.67 (1.31–2.14) <0.001
I 155 (23.8)
II 263 (40.5)
III 218 (33.5)
Venous invasion No 266 (40.9) 1.26 (0.87–1.82) 0.217
Yes 384 (59.1)
Tumour location Right and transverse 247 (38.0) 0.84 (0.58–1.23) 0.373
Left 145 (22.3)
Rectum 237 (36.5)
Total and subtotal 21 (3.2)
Adjuvant chemotherapy No 463 (71.2) 0.70 (0.45–1.08) 0.102
Yes 187 (28.8)
Systemic inflammation
mGPS 0 499 (76.8) 1.55 (1.25–1.91) <0.001
1 63 (9.7)
2 88 (13.5)
NLR ≤3 369 (56.8) 1.40 (0.98–1.99) 0.066
>3 281 (43.2)
NPS 0 568 (87.4) 1.66 (1.16–2.36) 0.005
1 67 (10.3)
2 15 (2.3)
Body composition
BMI (kg/m2) <25 29 (4.5) 0.60 (0.39–0.91) 0.0154
≥25 190 (29.2)
High SFI No 116 (17.8) 0.60 (0.40–0.89) 0.011
Yes 534 (82.2)
Visceral obesity No 177 (27.2) 0.68 (0.47–0.98) 0.040
Yes 473 (72.8)
Low SMI (sarcopenia)
SMI (Martin) No 367 (56.5) 1.74 (1.21–2.49) 0.003
Yes 283 (43.5)
SMI (Dolan BMI ≥ 25) No 371 (57.1) 1.77 (1.24–1.54) 0.002
Yes 279 (42.9)
SMI (Caan) No 313 (48.2) 1.58 (1.09–2.28) 0.016
Yes 337 (51.8)
SMI (Dolan BMI ≥ 30) No 386 (59.4) 1.60 (1.12–2.28) 0.010
Yes 264 (40.6)
Low SMD (myosteatosis)
SMD (Martin) No 258 (39.7) 1.84 (1.25–2.72) 0.002
Yes 392 (60.3)
SMD (Dolan BMI ≥ 25) No 343 (52.8) 1.57 (1.10–2.25) 0.013
Yes 307 (47.2)
SMD (Xiao) No 309 (47.5) 1.54 (1.07–2.22) 0.020
Yes 341 (52.5)
SMD (Dolan Male/Female) No 304 (46.8) 1.58 (1.10–2.27) 0.014
Yes 346 (53.2)
BMI, body mass index; CI, confidence interval; HR, hazard ratio; mGPS, modified Glasgow prognostic score; NLR, neutrophil lymphocyte
ratio; NPS, neutrophil-platelet score; SFI, subcutaneous fat index; SMD, skeletal muscle density; SMI, skeletal muscle index.
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patients and according to BMI, which are summarized in
Table 1. In the present study, SMI (Dolan) thresholds were
derived using receiver operating characteristic curve analysis
to determine thresholds associated with overall survival
in this population. This was also conducted using validated
online biomarker cut-off optimization software.29 In male
patients, the clinically significant cut-off for SMI with a
BMI < 25 was 45 cm2/m2 and for male patients with a
BMI ≥ 25 was 53 cm2/m2. The clinically significant cut-off
for SMI in female patients with a BMI < 25 was 39 cm2/m2
and for female patients with a BMI ≥ 25 was 41 cm2/m2.
Given that these SMI threshold values (Dolan BMI ≥ 25)
were similar to those of Martin (Table 1) and to facilitate
comparison of studies, the threshold values of Martin
were used in the analysis. In addition, the association be-
tween sarcopenia (Martin) and sarcopenia (Dolan BMI ≥ 25)
was strong (P < 0.001). For example, when Martin et al.
thresholds were used, 43.5% of patients had sarcopenia,
and when Dolan et al. thresholds were used, 42.9% of
patients had sarcopenia (Table 1).
In the present study in male patients, the clinically signifi-
cant cut-off for SMI with a BMI < 30 was 45.6 cm2/m2 and
for male patients with a BMI ≥ 30 was 56.8 cm2/m2.
The clinically significant cut-off for SMI in female patients
with a BMI < 30 was 39.1 cm2/m2 and for female patients
with a BMI ≥ 30 was 44.6 cm2/m2. Given that these SMI
threshold values (Dolan BMI ≥ 30) were not similar to those
of Caan (Table 1), the threshold values of Caan were not used
in the subsequent analysis.
With reference to SMD, Martin et al. in 1473 patients
with multistage lung and gastrointestinal cancers defined
SMD (myosteatosis) as an SMD < 41 HU in patients with
BMI < 25 kg/m2 and <33 HU in patients with
BMI ≥ 25 kg/m.6 In contrast, Xiao et al. in 3051 non-
metastatic stage I–III CRC defined myosteatosis according
to sex as <35.5 HU in men and <32.5 HU in women.26 In the
present study, SMD (Dolan) thresholds were derived
using receiver operating characteristic curve analysis to
determine thresholds associated with overall survival in this
population. This was also conducted using validated online
biomarker cut-off optimization software.29 The clinically
significant cut-off for SMD in patients in the present cohort
with a BMI < 25 was 34 HU and for patients with a BMI ≥ 25
was 32 HU. Given that these SMD threshold values (Dolan
BMI ≥ 25) were not similar to those of Martin, the
threshold values of Martin were not used in the subsequent
analysis.
In the present study, the clinically significant cut-off for
SMD in male patients was 34.1 HU and in female patients was
34.4 HU. Given that these SMD threshold values (Dolan
Male/Female) were similar to Xiao and to facilitate compari-
son of studies, the threshold values of Xiao were used
in the analysis. In addition, the association between
SMD (Xiao) and SMD (Dolan Male/Female) was strong
(P < 0.001). For example, when Xiao et al. thresholds were
used, 47.5% of patients had myosteatosis, and when
Dolan et al. thresholds were used, 46.8% of patients had
myosteatosis.
The relationship between clinicopathological characteris-
tics, body composition, and overall survival is shown in
Table 2. The majority of patients were over 65 years of age
(64%), overweight or obese (68%), with some co-morbidities
(88%) and node negative disease (67%). The majority of
tumours were located in the right colon (38%) and rectum
(37%), and an open surgical approach was applied in 62% of
cases. A total of 528 patients were alive at the censor date
with a median survival of 44 months (range 1–110 months).
Deaths by any cause occurred in 122 patients (18%), 71
(11%) of which were cancer specific. On univariate survival
analysis, age, ASA, TNM stage, and mGPS were significantly
associated with overall survival (all P < 0.001). Of the body
composition parameters, BMI, SFI, VO, SMI (Martin, Dolan,
and Caan), and SMD (Martin, Dolan, and Xiao) were
significantly associated with overall survival (all P < 0.05).
Skeletal muscle index and SMD were weakly associated
(Figure 1). Comparing SMI (Martin) and SMD (Xiao), both
SMI (HR 1.68, 95% CI 1.17–2.41, P = 0.005) and SMD (HR
1.47, 95% CI 1.02–2.11, P = 0.040) were independently asso-
ciated with overall survival.
The relationship between SMI (Martin), SMD (Xiao), and
mGPS and the clinicopathological characteristics is shown
in Tables 3–5, respectively. A low SMI (Martin) was signifi-
cantly associated with older age, higher mGPS, lower
BMI, and lower SMD (Martin, Dolan, and Xiao) (all
P < 0.001). A low SMD (Xiao) was significantly associated
with older age, female sex, higher ASA a right-sided tumour,
mGPS, lower BMI, SFI, VO, and lower SMI (Martin,
Dolan, and Xiao) (all P < 0.05). An elevated mGPS was
Figure 1 The relationship between skeletal muscle index (SMI) and
skeletal muscle density (SMD) in patients undergoing elective surgery
for colorectal cancer (n = 650).
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significantly associated with a high ASA, TNM stage, tumour
location, NLR, neutrophil-platelet score, BMI ≥ 25, SMI
(Martin, Dolan, and Caan), and SMD (Martin and Dolan)
(all P < 0.05).
The relationship between SMI (Martin) high/low groups,
SMD (Xiao) high/low groups, and mGPS high/low groups
and overall survival is shown in Figure 2. Comparing
SMI (Martin), SMD (Xiao), and mGPS, SMI (Martin)
Table 3 The relationship between sarcopenia (Martin), clinicopathological characteristics, and systemic inflammation in patients undergoing elective
surgery for colorectal cancer (n = 650)
Characteristic High SMI (no sarcopenia n = 367) Low SMI (sarcopenia n = 283) P-value
Clinicopathological
Age ≤65 160 (43.6) 74 (26.1) <0.001
65–74 133 (36.2) 118 (41.7)
>74 74 (20.2) 91 (32.2)
Sex Female 163 (44.4) 133 (47.0) 0.513
Male 204 (55.6) 150 (53.0)
ASA score 1 81 (22.1) 60 (21.2) 0.159
2 167 (45.5) 130 (45.9)
3 113 (30.8) 80 (28.3)
4 6 (1.6) 13 (4.6)
Laparoscopic surgery No 220 (59.9) 187 (66.1) 0.109
Yes 147 (40.1) 96 (33.9)
TNM 0 9 (2.5) 5 (1.8) 0.032
I 101 (27.5) 54 (19.1)
II 133 (36.2) 130 (45.9)
III 124 (33.8) 94 (33.2)
Venous invasion No 154 (42.0) 112 (39.6) 0.540
Yes 213 (58.0) 171 (60.4)
Tumour location Right and transverse 138 (37.6) 109 (38.5) 0.293
Left 77 (21.0) 68 (24.0)
Rectum 143 (39.0) 94 (33.2)
Total and subtotal 9 (2.5) 12 (4.2)
Adjuvant chemotherapy No 208 (56.7) 177 (62.5) 0.091
Yes 159 (43.3) 106 (37.5)
Systemic inflammation
mGPS 0 298 (81.2) 201 (71.0) <0.001
1 39 (10.6) 24 (8.5)
2 30 (8.2) 58 (20.5)
NLR ≤3 220 (59.9) 149 (52.7) 0.063
>3 147 (40.1) 134 (47.3)
NPS 0 328 (89.4) 240 (84.8) 0.220
1 32 (8.7) 35 (12.4)
2 7 (1.9) 8 (2.8)
Body composition
BMI (kg/m2) <25 103 (28.1) 116 (41) 0.001
≥25 264 (71.9) 167 (59)
High SFI No 67 (18.3) 49 (17.3) 0.756
Yes 300 (81.7) 234 (82.7)
Visceral obesity No 98 (26.7) 79 (27.9) 0.731
Yes 269 (73.3) 204 (72.1)
Low
SMI (sarcopenia)
SMI
(Dolan BMI ≥ 25)
No 356 (97.0) 15 (5.3) <0.001
Yes 11 (3.0) 268 (94.7)
SMI (Caan) No 275 (74.9) 38 (13.4) <0.001
Yes 92 (25.1) 245 (86.6)
SMI
(Dolan BMI ≥ 30)
No 315 (85.8) 71 (25.1) <0.001
Yes 52 (14.2) 212 (74.9)
Low
SMD (myosteatosis)
SMD (Martin) No 177 (48.2) 81 (28.6) <0.001
Yes 190 (51.8) 202 (71.4)
SMD
(Dolan BMI ≥ 25)
No 224 (61.0) 119 (42.0) <0.001
Yes 143 (39.0) 164 (58.0)
SMD (Xiao) No 196 (53.4) 113 (39.9) 0.001
Yes 171 (46.6) 170 (60.1)
SMD
(Dolan BMI Male/Female)
No 197 (53.7) 107 (37.8) <0.001
Yes 170 (46.3) 176 (62.2)
BMI, body mass index; mGPS, modified Glasgow prognostic score; NLR, neutrophil lymphocyte ratio; NPS, neutrophil-platelet score; SFI,
subcutaneous fat index; SMD, skeletal muscle density; SMI, skeletal muscle index.
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Table 4 The relationship between SMD (Xiao), clinicopathological characteristics, and systemic inflammation in patients undergoing surgery for colo-
rectal cancer (n = 650)
Characteristic
Low SMD (Xiao)
No (n = 309) Yes (n = 341) P-value
Clinicopathological
Age ≤65 149 (48.2) 85 (24.9) <0.001
65–74 108 (35.0) 143 (41.9)
>75 52 (16.8) 113 (33.1)
Sex Female 167 (54.0) 129 (37.8) <0.001
Male 142 (46.0) 212 (62.2)
ASA score 1 91 (29.4) 50 (14.7) <0.001
2 140 (45.3) 157 (46.0)
3 72 (23.3) 121 (35.5)
4 6 (1.9) 13 (3.8)
Laparoscopic surgery No 195 (63.1) 212 (62.2) 0.805
Yes 114 (36.9) 129 (37.8)
TNM 0 7 (2.3) 7 (2.1) 0.934
I 77 (24.9) 78 (22.9)
II 123 (39.8) 140 (41.1)
III 102 (33.0) 116 (34.0)
T stage 0 7 (2.3) 7 (2.1) 0.327
1 34 (11.0) 45 (13.2)
2 59 (19.1) 45 (13.2)
3 160 (51.8) 184 (54.0)
4 49 (15.9) 60 (17.6)
N stage 0 208 (67.3) 226 (66.3) 0.898
1 76 (24.6) 84 (24.6)
2 25 (8.1) 31 (9.1)
Venous invasion No 133 (43.0) 133 (39.0) 0.296.0
Yes 176 (57.0) 208 (61.0)
Tumour location Right and transverse 108 (35.0) 139 (40.8) 0.041
Left 64 (20.7) 81 (23.8)
Rectum 127 (41.1) 110 (32.3)
Total and subtotal 10 (3.2) 11 (3.2)
Adjuvant chemotherapy No 103 (33.3) 84 (24.6) 0.027
Yes 206 (66.7) 257 (75.4)
Systemic inflammation
mGPS 0 242 (78.3) 257 (75.4) 0.045
1 35 (11.3) 28 (8.2)
2 32 (10.4) 56 (16.4)
NLR ≤3 183 (59.2) 186 (54.5) 0.229
>3 126 (40.8) 155 (45.5)
NPS 0 273 (88.3) 295 (86.5) 0.738
1 30 (9.7) 37 (10.9)
2 6 (1.9) 9 (2.6)
Body composition
BMI (kg/m2) <25 136 (44.0) 83 (24.3) <0.001
≥25 173 (56.0) 258 (75.7)
High SFI No 76 (24.6) 40 (11.7) <0.001
Yes 233 (75.4) 301 (88.3)
Visceral obesity No 126 (40.8) 51 (15.0) <0.001
Yes 183 (59.2) 290 (85.0)
Sarcopenia
Low SMI
(Martin)
No 196 (63.4) 171 (50.1) <0.001
Yes 113 (36.6) 170 (49.9)
Low SMI (Dolan BMI ≥ 25) No 204 (66.0) 167 (49.0) <0.001
Yes 105 (34.0) 174 (51.0)
Low SMI (Caan) No 179 (57.9) 134 (39.3) <0.001
Yes 130 (42.1) 207 (60.7)
Low SMI (Dolan BMI ≥ 30) No 211 (68.3) 175 (51.3) <0.001
Yes 98 (31.7) 166 (48.7)
Myosteatosis
Low SMD (Martin) No 233 (75.4) 25 (7.3) <0.001
Yes 76 (24.6) 316 (92.7)
Low SMD (Dolan BMI ≥ 25) No 303 (98.1) 40 (11.7) <0.001
Yes 6 (1.9) 301 (88.3)
Low SMD (Dolan Male/Female) No 284 (91.8) 20 (5.9) <0.001
Yes 25 (8.1) 321 (94.1)
BMI, body mass index; mGPS, modified Glasgow prognostic score; NLR, neutrophil lymphocyte ratio; NPS, neutrophil-platelet score; SFI,
subcutaneous fat index; SMD, skeletal muscle density; SMI, skeletal muscle index.
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(HR 1.50, 95% CI 1.04–2.18, P = 0.031), SMD (Xiao) (HR 1.42,
95% CI 0.98–2.05, P = 0.061), and mGPS (HR 1.44, 95% CI
1.15–1.79, P = 0.001) were independently associated with
overall survival (Table 6).
In patients with an mGPS of 0, SMI (Martin) (HR 1.48,
95% CI 0.97–2.28, P = 0.071) and SMD (Xiao) (HR 1.50,
95% CI 0.97–2.33, P = 0.068) were weakly associated with
overall survival (Table 6). In patients with an mGPS of 0,
SMI (Martin) (HR 2.02, 95% CI 0.98–4.18, P = 0.058) was
weakly associated with overall survival (Table 6).
Low SMI (Martin) was present in 40% of patients with an
mGPS of 0. In contrast, low SMI (Martin) was present in
Table 5 The relationship between mGPS, clinicopathological characteristic, and systemic inflammation in patients undergoing elective surgery for
colorectal cancer (n = 650)
Characteristic mGPS 0 mGPS 1 and 2 (n = 151) P-value
Clinicopathological
Age ≤65 185 (37.1) 49 (32.5) 0.410
65–74 193 (38.7) 58 (38.4)
>74 121 (24.2) 44 (29.1)
Sex Female 228 (45.7) 68 (45.0) 0.887
Male 271 (54.3) 83 (55.0)
ASA score 1 120 (24.0) 21 (13.9) 0.036
2 221 (44.3) 76 (50.3)
3 146 (29.3) 47 (31.1)
4 12 (2.4) 7 (4.6)
Laparoscopic surgery No 303 (60.7) 104 (68.9) 0.070
Yes 196 (39.3) 47 (31.1)
TNM 0 13 (2.6) 1 (0.7) <0.001
I 135 (27.1) 20 (13.2)
II 173 (34.7) 90 (59.6)
III 178 (35.7) 40 (26.5)
Venous invasion No 199 (39.9) 67 (44.4) 0.325
Yes 300 (60.1) 84 (55.6)
Tumour location Right and transverse 175 (35.1) 72 (47.7) 0.014
Left 112 (22.4) 33 (21.9)
Rectum 197 (39.5) 40 (26.5)
Total and subtotal 15 (3.0) 6 (4.0)
Adjuvant chemotherapy No 293 (66.9) 92 (68.7) 0.704
Yes 206 (33.1) 59 (31.3)
Systemic inflammation
NLR ≤3 308 (61.7) 61 (40.4) <0.001
>3 191 (38.3) 90 (59.6)
NPS 0 459 (92.0) 109 (72.2) <0.001
1 38 (7.6) 29 (19.2)
2 2 (0.4) 13 (8.6)
Body composition
BMI (kg/m2) <25 156 (31.3) 63 (41.7) 0.017
≥25 343 (68.7) 88 (58.3)
High SFI No 84 (16.8) 32 (21.2) 0.220
Yes 415 (83.2) 119 (78.8)
Visceral obesity No 129 (25.9) 48 (31.8) 0.151
Yes 370 (74.1) 103 (68.2)
Low SMI (sarcopenia)
SMI (Martin) No 298 (59.7) 69 (45.7) 0.002
Yes 201 (40.3) 82 (54.3)
SMI (Dolan BMI ≥ 25) No 299 (59.9) 72 (47.7) 0.008
Yes 200 (40.1) 79 (52.3)
SMI (Caan) No 254 (50.9) 59 (39.1) 0.011
Yes 245 (49.1) 92 (60.9)
SMI (Dolan BMI ≥ 30) No 309 (61.9) 77 (51.0) 0.017
Yes 190 (38.1) 74 (49.0)
Low SMD (myosteatosis)
SMD (Martin) No 214 (42.9) 44 (29.1) 0.002
Yes 285(57.1) 107 (70.9)
SMD (Dolan BMI ≥ 25) No 274 (54.9) 69 (45.7) 0.047
Yes 225 (45.1) 82 (54.3)
SMD (Xiao) No 242 (48.5) 67 (44.4) 0.374
Yes 257 (51.5) 84 (55.6)
SMD (Dolan Male/Female) No 241 (48.3) 63 (41.7) 0.156
Yes 258 (51.7) 88 (58.3)
BMI, body mass index; mGPS, modified Glasgow prognostic score; NLR, neutrophil lymphocyte ratio; NPS, neutrophil-platelet score; SFI,
subcutaneous fat index; SMD, skeletal muscle density; SMI, skeletal muscle index.
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66% of patients with an mGPS of 2. Low SMD (Xiao) was pres-
ent in 52% of patients with an mGPS of 0. In contrast, SMD
(Xiao) was present in 64% of patients with an mGPS of 2. A
combination of low SMI (Martin) and low SMD (Xiao) was
present with an mGPS 0 in 23.4% of patients. In contrast,
a combination of low SMI (Martin) and low SMD (Martin)
was present with an mGPS 2 in 45.5% of patients.
Discussion
The results of the present comprehensive study, in patients
with CRC who were largely overweight, and using CT-derived
body composition analysis, showed that sarcopenia (SMI)
and myosteatosis (SMD) were significantly associated with
survival. Moreover, SMI and SMD were associated with the
presence of a systemic inflammatory (in particular the mGPS)
and had independent prognostic value. Therefore, the
present results support the routine measurement of the
SMI, SMD, and mGPS as part of the clinical and nutritional
assessment in patients with cancer.3,23,30
Colorectal cancer has been extensively examined with
reference to CT-derived body composition, and most stud-
ies have reported that either SMI or SMD is associated with
survival. In contrast, few studies have included a measure-
ment of the systemic inflammatory response in their analy-
sis. In those studies that included a white cell measure of
Figure 2 (A) The relationship between skeletal muscle index (SMI) (Martin) and overall survival (n = 650, P = 0.002). (B) The relationship between
skeletal muscle density (SMD) (Xiao) and overall survival (n = 650, P = 0.019). (C) The relationship between modified Glasgow prognostic score (mGPS)
and overall survival (n = 650, P = 0.010).
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the systemic inflammatory response such as NLR, SMI and
SMD were reported to be independently associated with
survival.17,22 Irrespective, the systemic inflammatory re-
sponse (however measured) is associated with lower SMI
and SMD. These observations may have profound implica-
tions for the treatment of sarcopenia and myosteatosis in
patients with CRC and, potentially, other common solid
tumours.
Such cross-sectional data cannot determine whether a low
SMI or SMD results in the presence of systemic inflammation
or whether the presence of systemic inflammation results in
low SMI or SMD. From the present results, it is clear that a
low SMI, SMD, or both can occur in the absence of systemic
inflammation. However, the proportion of patients with a
low SMI, SMD, or both are substantially greater in the
presence of systemic inflammation. It may be that in those
patients that simply improving dietary intake and activity will
improve SMI and SMD. In contrast, in those patients with an
mGPS 1/2, it may be that moderation of the systemic
inflammatory response is required in addition to improve
SMI and SMD.15 In order to better understand the nature of
this relationship, it will be important to carry out longitudinal
and intervention studies.
With reference to longitudinal studies, Wallengren et al.
reported that, in 471 patients with advanced cancer, a
C-reactive protein > 10 mg/L had less muscle mass (using
dual energy X-ray absorptiometry) on study entry and lost
muscle at an accelerated rate during follow-up.31 Malietzis
et al. reported that, in 856 patient with operable CRC, an
NLR > 3 was associated with lower muscle mass (CT scan)
over time.32 Both studies concluded that systemic inflamma-
tion was a risk factor for muscle loss and may be a useful
marker of catabolic drive. However, the loss of
muscle quality has yet to be examined in this relationship.
Therefore, further longitudinal studies are required if the
relationship between skeletal muscle mass and quality, the
systemic inflammatory response and survival is to be further
elucidated. To our knowledge, the above relationship has not
been examined in interventional studies.
It was of interest that, in the present study, ~50% of
patients had a low SMI or SMD. Compared with other cohorts
of patients with early stage CRC treated with surgical resec-
tion, these figures appear high and similar to that reported
in the terminal stage of the disease. Given that these percent-
ages were similar using various thresholds of Dolan, Martin,
Caan, and Xiao for patients in this cohort, this may suggest
that there is a baseline level of poor muscle quantity and
quality within this population. This is perhaps not surprising
given the deprivation levels of patients referred to Glasgow
Royal Infirmary. Indeed, in Glasgow, 190 000 or just under
32% of the city’s population resides in the 10% of the most
deprived areas of the UK (the so-called Glasgow effect).
This is associated with a poor diet and physical fitness and
high levels of alcohol consumption and smoking, which would
have a direct effect on both muscle quantity and quality.
Indeed, when direct comparisons are made with functional
testing such as the ASA scoring in the present and other
reported studies, for example, in the present study, 33% of
patients had an ASA score of ≥3 (severe systemic disease)
compared with a recent combined study of 2100 UK and
Canadian patients undergoing elective surgery for CRCs
where 20% had an ASA score of ≥3.33 In addition, when the
763 UK-based patients of this study were examined in
isolation, 11% had an ASA score of ≥3.17 Therefore, it is
clear that the present patient cohort had higher levels of
co-morbid disease and lower levels of physical function and
this may account for, in part, the high percentage of patients
with a low SMI and SMD.
Indeed, it was of interest that in the present study, ASA
was significantly associated with SMD and not SMI. A similar
relationship has recently been reported between SMD but
not SMI and the Charleston co-morbidity index.26 This
confirms the clinical utility of SMD as there is increasing
recognition that an increase in muscle mass is not necessarily
associated with an increase in function.34,35 It may be that
an improvement in muscle quality rather than mass will
result in an improvement in physical function.
Limitations of the present study include its retrospective
nature and that only patients with an electronically available
CT scan were included. However, the study population was
relatively large, well documented in terms of clinicopatholog-
ical characteristics and measures of the systemic inflamma-
tory response and relatively mature follow-up. Furthermore,
different validated threshold values were applied to the CT
body composition parameters.
In summary, the present study provides comprehensive ev-
idence that both low skeletal muscle mass and quality has a
significant relationship to the systemic inflammatory re-
sponse and to survival in patients with operable CRC. This
supports the incorporation of the SMI, SMD, and mGPS as
part of the clinical and nutritional assessment in patients with
Table 6 The relationship between SMI, SMD, mGPS, sarcopenia, and
overall survival in patients undergoing elective surgery for colorectal can-
cer (n = 650)
Independent, mutually
adjusted association HR (95% CI) P-value
All Patients n = 650
mGPS 1.44 (1.15–1.79) 0.001
Low SMI (Martin) 1.50 (1.04–2.18) 0.031
Low SMD (Xiao) 1.42 (0.98–2.05) 0.061
mGPS 0 n = 499
Low SMI (Martin) 1.48 (0.97–2.28) 0.071
Low SMD (Xiao) 1.50 (0.97–2.33) 0.068
mGPS 1/21 n = 151
Low SMI (Martin) 2.02 (0.98–4.18) 0.058
Low SMD (Xiao) 1.30 (0.67–2.54) 0.438
CI, confidence interval; HR, hazard ratio; mGPS, modified Glasgow
prognostic score; SMD, skeletal muscle density; SMI, skeletal mus-
cle index.
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cancer. This relationship also suggests potential therapeutic
interventions.
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